Plasma exchange and radiation resensitize immunotherapy-refractory melanoma: a phase I trial

Plasma exchange and radiation resensitize immunotherapy-refractory melanoma: a phase I trial

Abstract Immune checkpoint inhibitors (ICI) are effective for advanced melanoma. However, most develop ICI resistance. Tumor-derived soluble PD-L1 (sPD-L1) and other immunosuppressive factors drive resistance. We hypothesized that therapeutic plasma exchange (TPE) may remove sPD-L1 from circulation...

Full description

Saved in:
Bibliographic Details
Main Authors: Jacob J. Orme, Henan Zhang, Prashanth Lingamaneni, Yohan Kim, Roxane Lavoie, Maddy Dorr, Paul Dizona, Jacob Hirdler, Elizabeth A. Bering, Joanina K. Gicobi, Michelle Hsu, Heather Dale, Daniel S. Childs, Lisa A. Kottschade, Robert R. McWilliams, Matthew S. Block, Aaron S. Mansfield, Svetomir N. Markovic, Ken Olivier, Dawn Owen, Scott Lester, Daniel Ma, Roxana S. Dronca, Haidong Dong, Fabrice Lucien, Annie T. Packard, Jeffrey L. Winters, Sean S. Park
Format: Article
Language:English
Published: Nature Portfolio 2025-03-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-025-57865-9
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41467-025-57865-9

Similar Items